Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | NKR-2 cells |
Trade Name | |
Synonyms | NKG2D CAR-T cells|CYAD-01|CYAD-101 |
Drug Descriptions |
NKR-2 cells are T-lymphocytes engineered to express a chimeric antigen receptor consists of human natural killer receptor (NKG2D) and the human CD3 zeta signaling domain, which may results in anti-tumor immunity (J Clin Oncol 35, 2017 (suppl; abstr TPS3093), PMID: 29133316). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C121536 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Fluorouracil + Irinotecan + Leucovorin + NKR-2 cells | Fluorouracil Irinotecan Leucovorin NKR-2 cells | 0 | 1 |
Fluorouracil + Leucovorin + NKR-2 cells + Oxaliplatin | Fluorouracil Leucovorin NKR-2 cells Oxaliplatin | 0 | 1 |
Fluorouracil + Leucovorin + NKR-2 cells + Oxaliplatin + Pembrolizumab | Fluorouracil Leucovorin NKR-2 cells Oxaliplatin Pembrolizumab | 0 | 1 |
NKR-2 cells | NKR-2 cells | 0 | 1 |